CANbridge Pharmaceuticals

About:

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

Website: http://www.canbridgepharma.com/

Top Investors: General Atlantic, RA Capital Management, Qiming Venture Partners, WuXi AppTec, LYFE Capital

Description:

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

Total Funding Amount:

$224M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Beijing, Beijing, China

Founded Date:

2012-01-01

Contact Email:

info(AT)canbridgepharma.com

Founders:

James Xue

Number of Employees:

101-250

Last Funding Date:

2020-12-01

IPO Status:

Public

Industries:

© 2025 bioDAO.ai